This community-based cohort study examined relationships between plasma Alzheimer's disease (AD) biomarkers measured by NULISAseq and cerebral amyloid (Aβ) deposition quantified with 18F-Florbetaben PET in cognitively unimpaired, late middle-aged adults. The analysis focused on biomarkers tied to AD pathology, including Aβ isoforms, total and brain-derived phosphorylated-tau species, and proteins implicated in amyloid processing and neuronal health.
The cohort comprised 541 participants drawn from Hispanic, non-Hispanic Black, and non-Hispanic White groups. All participants were cognitively unimpaired and underwent 18F-Florbetaben PET imaging to assess brain Aβ deposition. Plasma biomarkers were measured using the NULISAseq platform and analyses were restricted to markers related to AD pathology: Aβ38, Aβ40, Aβ42, ACHE, BACE1, BASP1, BD-p-tau181, BD-p-tau217, CD63, IGFBP7, KLK6, MAPT-tau, PSEN1, SFRP1, total p-tau181, p-tau217, and p-tau231.
Researchers used bidirectional stepwise linear regression to identify plasma biomarkers associated with brain Aβ deposition. Kidney function was evaluated using cystatin C–based estimated glomerular filtration rate (eGFR) and categorized by chronic kidney disease (CKD) stage: normal/high (≥90 mL/min/1.73 m2), mildly decreased (60–89 mL/min/1.73 m2), and moderately/severely decreased or failure (<60 mL/min/1.73 m2). Linear regression models then tested interactions between plasma biomarkers and CKD stage to assess effect modification by kidney function.
Stepwise regression retained several plasma markers as significantly associated with brain Aβ deposition. BD-p-tau217 emerged as the strongest positive correlate of brain amyloid (B = 0.22; 95% CI 0.19 to 0.25; p < 0.001). In contrast, plasma Aβ42 was negatively associated with brain Aβ deposition (B = −0.08; 95% CI −0.11 to −0.06; p < 0.001). Two additional markers—IGFBP7 (B = −0.05; 95% CI −0.08 to −0.02; p = 0.004) and BACE1 (B = −0.04; 95% CI −0.07 to −0.01; p = 0.009)—were also retained and showed negative associations with brain Aβ deposition.
These retained biomarkers represent different biological aspects: BD-p-tau217 reflects brain-derived phosphorylated tau species linked to AD tauopathy, while Aβ42, IGFBP7, and BACE1 relate to amyloid peptide levels, insulin-like growth factor binding, and beta-site APP–cleaving enzyme activity, respectively.
Models testing biomarker-by-CKD stage interactions identified a significant interaction for BD-p-tau217. Specifically, the positive association between BD-p-tau217 and brain Aβ deposition was weaker among individuals with moderately/severely decreased kidney function or kidney failure compared with individuals with normal/high kidney function (interaction B = −0.17; 95% CI −0.25 to −0.08; p < 0.001). This finding indicates that reduced kidney function may attenuate the plasma BD-p-tau217 signal in relation to brain amyloid burden.
No additional interaction details for other biomarkers were reported in the source text.
In this real-world, community-based sample, BD-p-tau217 was the plasma biomarker most strongly associated with brain Aβ deposition measured by PET, supporting its potential utility as a blood-based screen for AD pathology in asymptomatic, late middle-aged adults. The negative associations observed for plasma Aβ42, IGFBP7, and BACE1 suggest these markers may also reflect processes related to cerebral amyloid but in the opposite direction.
The observed attenuation of the BD-p-tau217–brain Aβ relationship in participants with moderate to severe kidney dysfunction or failure highlights kidney function as a potential modifier of plasma biomarker performance. This suggests that when interpreting plasma BD-p-tau217 levels, clinicians and researchers should consider renal function, as decreased eGFR may reduce the strength of the biomarker–PET association.
IGFBP7 and BACE1 were proposed as candidate plasma biomarkers of brain Aβ deposition; the authors recommend replication of these findings in independent cohorts before clinical application.
The source reports that additional anonymized data not published within the article will be made available by request to qualified investigators. Ethical approval was obtained from the Institutional Review Board of Columbia University. The preprint lists funding from multiple NIH and National Institute on Aging awards. Competing interests are disclosed for certain authors; most authors reported no conflicts. Detailed limitations beyond those explicitly described in the source text were not reported in the provided extract.